Unraveling the routes to distant metastases in colorectal cancer: Tumor deposits and lymph node metastases as the gateway

IF 20.1 1区 医学 Q1 ONCOLOGY Cancer Communications Pub Date : 2024-08-25 DOI:10.1002/cac2.12598
Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Shannon van Vliet, Natasja Rutgers, Nikki Knijn, Gesina van Lijnschoten, Jessica Juliana Tan, Johannes Hendrik Willem de Wilt, Niek Hugen, Gina Brown, Femke Simmer, Iris Dionne Nagtegaal
{"title":"Unraveling the routes to distant metastases in colorectal cancer: Tumor deposits and lymph node metastases as the gateway","authors":"Nelleke Pietronella Maria Brouwer,&nbsp;Ayse Selcen Oguz Erdogan,&nbsp;Shannon van Vliet,&nbsp;Natasja Rutgers,&nbsp;Nikki Knijn,&nbsp;Gesina van Lijnschoten,&nbsp;Jessica Juliana Tan,&nbsp;Johannes Hendrik Willem de Wilt,&nbsp;Niek Hugen,&nbsp;Gina Brown,&nbsp;Femke Simmer,&nbsp;Iris Dionne Nagtegaal","doi":"10.1002/cac2.12598","DOIUrl":null,"url":null,"abstract":"<p>Currently, lymph node metastases (LNM) are seen as the gateway to distant metastases in CRC and play a crucial role in the Tumor Node Metastasis (TNM) staging system [<span>1, 2</span>]. Tumor deposits (TD) have been identified as another histological feature with a strong prognostic impact but are currently only deemed clinically relevant in the absence of LNM [<span>2, 3</span>]. TD are clusters of tumor cells in the fat surrounding the bowel and are often associated with nerves, vessels and lymphatic tissue, giving the cancer cells access to multiple routes of spread [<span>4</span>].</p><p>To study whether TD could indeed form an alternative gateway to distant metastases, we have used polyG-based phylogenetics on formalin-fixed paraffin-embedded (FFPE) tissue to investigate the role of histologically defined TD and LNM in CRC evolution and distant metastatic spread to the liver and peritoneum.</p><p>We collected data from patients who were diagnosed with colorectal liver or peritoneal metastases between January 2015 and January 2022 and not previously treated with chemotherapy. DNA was isolated from the TD and LNM (Figure 1A), normal tissue (which was sampled at the edge of the resection specimen) and distant metastases. Three distinct tissue parts of the primary tumor were sampled to account for intra-tumor heterogeneity (Figure 1B), yielding a total of 480 samples (Supplementary Table S1). Polymerase chain reaction (PCR) was used to genotype up to 24 polyG regions for every sample (Supplementary Table S2). Sequentially, phylogenetic trees were constructed based on the peak distribution of all PCR results from the polyG regions using an analysis pipeline previously developed by Naxerova et al. in R software (version 4.3.1) [<span>5</span>]. Phylogenetic trees are graphical representations of the evolutionary relationship between biological entities, in this case, the different tissue samples. After quality control of PCR results (i.e., poor quality DNA), impurity (i.e., contamination of samples with non-tumorous cells, Supplementary Figure S1), and branching confidence (i.e., values &lt; 50% were deemed unreliable), 47 CRC patients with a total of 43 individual liver metastases and 30 individual peritoneal metastases were included in the final results (Supplementary Table S3-S5). The distribution of origins (TD, LNM, primary tumor or a mix of these) was compared between the group of liver and the group of peritoneal metastases using Fisher's exact test. Potential confounding clinicopathological factors were analyzed using the Kruskal-Wallis of Fisher's exact test. <i>P</i> values &lt; 0.05 were considered significant. Full descriptions of the materials and methods are provided in the Supplementary Materials.</p><p>Phylogenetic analysis showed that the primary tumor, TD, and LNM could be possible origins of liver metastases. An exemplary phylogenetic tree is shown in Figure 1C, where different subclones gave rise to different LNMs, and several liver metastases with common ancestry were related to the TD. Taken together, TD, LNM, primary tumor or a mix of these were found to be the origin of liver metastases in 23%, 23%, 23% and 30%, respectively (Figure 1D). Several clinicopathological variables were tested for biasing the results, of which only the number of included TDs was significantly different between the liver metastases related to TD and PT (<i>P</i> = 0.03), all other comparisons showed no differences significantly with the number of metastases related to TD (Supplementary Figures S2-S3). Our data show that LNM can form a gateway to liver metastases in 23% of cases, which is in line with an earlier smaller study, where 0-35% of liver metastases were found to be related to LNM [<span>5</span>]. These results are in contrast with the idea that LNM is the main gateway to distant metastases, which is the basis for the current TNM staging system. Importantly, TD were identified as an alternative gateway in 23% of liver metastases, which confirms the prognostic evidence that shows an increased risk of liver metastases in patients with TD [<span>3</span>].</p><p>In contrast to liver metastases, peritoneal metastases were most often related to TD with 40% of cases and second most often to the primary tumor with 37%. LNMs or a mix of the different structures formed the origin in 7% and 10% of peritoneal metastases, respectively (Figure 1E). These results provide phylogenetic evidence that supports previous studies showing that the presence of TDs is associated with an increased risk of peritoneal metastases [<span>6</span>].</p><p>This study demonstrated a clear difference in the evolution of liver and peritoneal metastases, with a significantly different distribution of origins (<i>P</i> &lt; 0.05, Figure 1D-E) and 40% of peritoneal metastases versus 23% of liver metastases being related to TD. This could be explained by biologically different pathways to metastases. Liver metastases are thought to develop through the invasion-metastasis cascade where tumor cells spread to distant organs via the circulatory system [<span>7</span>]. Both LNMs and TDs formed possible gateways to liver metastases in the phylogenetic analyses and have their own way of accessing the systemic circulation. For LNMs, mouse studies showed that tumor cells could either invade small blood vessels surrounding the lymph node or travel through the lymphatic system and enter the systemic circulation at the thoracic duct [<span>8</span>]. Still, the exact mechanism is being widely debated, and in humans, the mechanism remains unclear. For TDs, it is more widely accepted that they have access to the blood circulation as it is reflected in their histology [<span>4</span>]. In line with literature, our study demonstrated a vascular component in 69% of TD related to liver metastases (Supplementary Figure S4). An alternative to the invasion-metastasis cascade has been proposed for peritoneal metastases involving more direct migration of tumor cells to the peritoneum [<span>7</span>]. We previously showed that the molecular phenotype needed for tumor cells to actively migrate to and invade the peritoneum is overexpressed in TD compared with LNM [<span>9</span>]. Therefore, it is likely that tumor cells with the ability to form TD are also capable of further migration through the serosal surface and invasion of the peritoneum, more so than the tumor cells in LNM.</p><p>There are some limitations to this study. Firstly, although all cases complied with the guideline quality of more than 12 sampled lymph nodes per CRC, and TD were scored by two pathologists and an expert researcher, there is a small chance that some TD or LNM were missed during the sampling of resection specimens. Secondly, it would be recommended that all phylogenetic studies be validated using a different method, such as whole genome or exome sequencing, to show whether the results are generalizable and robust [<span>10</span>]. Thirdly, due to time and financial restraints, this study only included the most common metastatic sites in CRC, liver and peritoneum. Including other metastatic sites would provide a more comprehensive overview of the process of metastatic spread in CRC.</p><p>In conclusion, with the use of phylogenic analysis, this study shows that both TDs and LNMs can be related to liver or peritoneal metastases in CRC. Moreover, the origin of metastases differs per metastatic site, with liver metastases being equally related to TDs and LNMs and peritoneal metastases being significantly more often related to TDs. Therefore, future research should focus on whether patients with TDs are at increased risk of peritoneal metastases, as this could impact follow-up and treatment decisions. Also, since we showed that a significant number of liver and peritoneal metastases were related to TDs, it should be questioned whether the current method of including TDs as less important than LNMs in the staging for CRC patients is justified. We propose that TDs should merit more attention by including them as equally important to LNMs in the nodal category and continuing to register them for future research.</p><p><i>Conceptualization</i>: Gina Brown, Femke Simmer, Iris Dionne Nagtegaal. <i>Methodology</i>: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Niek Hugen, Femke Simmer, Iris Dionne Nagtegaal. <i>Funding acquisition</i>: Gina Brown, Iris Dionne Nagtegaal. <i>Acquisition and analysis of data</i>: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Shannon van Vliet, Natasja Rutgers. <i>Statistical analysis</i>: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Shannon van Vliet, Natasja Rutgers, Femke Simmer. <i>Material support</i>: Nikki Knijn, Gesina van Lijnschoten, Jessica Juliana Tan, Gina Brown. <i>Writing—original draft</i>: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Niek Hugen, Femke Simmer, Iris Dionne Nagtegaal. <i>Writing—review &amp; editing</i>: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Shannon van Vliet, Natasja Rutgers, Nikki Knijn, Gesina van Lijnschoten, Jessica Juliana Tan, Johannes Hendrik Willem de Wilt, Niek Hugen, Gina Brown, Femke Simmer, Iris Dionne Nagtegaal.</p><p>All authors declare no conflicts of interest.</p><p>This study was supported by the Dutch Cancer Society (KUN 2019-12640).</p><p>The study was performed according to the Dutch “Federa, Human Tissue and Medical Research: Code of Conduct for Responsible Use (2011)” regulations, not requiring patient informed consent. This study was approved by the Ethics Committee (CMO) of the Radboudumc (approval number 2020-7172).</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":null,"pages":null},"PeriodicalIF":20.1000,"publicationDate":"2024-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.12598","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Communications","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cac2.12598","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, lymph node metastases (LNM) are seen as the gateway to distant metastases in CRC and play a crucial role in the Tumor Node Metastasis (TNM) staging system [1, 2]. Tumor deposits (TD) have been identified as another histological feature with a strong prognostic impact but are currently only deemed clinically relevant in the absence of LNM [2, 3]. TD are clusters of tumor cells in the fat surrounding the bowel and are often associated with nerves, vessels and lymphatic tissue, giving the cancer cells access to multiple routes of spread [4].

To study whether TD could indeed form an alternative gateway to distant metastases, we have used polyG-based phylogenetics on formalin-fixed paraffin-embedded (FFPE) tissue to investigate the role of histologically defined TD and LNM in CRC evolution and distant metastatic spread to the liver and peritoneum.

We collected data from patients who were diagnosed with colorectal liver or peritoneal metastases between January 2015 and January 2022 and not previously treated with chemotherapy. DNA was isolated from the TD and LNM (Figure 1A), normal tissue (which was sampled at the edge of the resection specimen) and distant metastases. Three distinct tissue parts of the primary tumor were sampled to account for intra-tumor heterogeneity (Figure 1B), yielding a total of 480 samples (Supplementary Table S1). Polymerase chain reaction (PCR) was used to genotype up to 24 polyG regions for every sample (Supplementary Table S2). Sequentially, phylogenetic trees were constructed based on the peak distribution of all PCR results from the polyG regions using an analysis pipeline previously developed by Naxerova et al. in R software (version 4.3.1) [5]. Phylogenetic trees are graphical representations of the evolutionary relationship between biological entities, in this case, the different tissue samples. After quality control of PCR results (i.e., poor quality DNA), impurity (i.e., contamination of samples with non-tumorous cells, Supplementary Figure S1), and branching confidence (i.e., values < 50% were deemed unreliable), 47 CRC patients with a total of 43 individual liver metastases and 30 individual peritoneal metastases were included in the final results (Supplementary Table S3-S5). The distribution of origins (TD, LNM, primary tumor or a mix of these) was compared between the group of liver and the group of peritoneal metastases using Fisher's exact test. Potential confounding clinicopathological factors were analyzed using the Kruskal-Wallis of Fisher's exact test. P values < 0.05 were considered significant. Full descriptions of the materials and methods are provided in the Supplementary Materials.

Phylogenetic analysis showed that the primary tumor, TD, and LNM could be possible origins of liver metastases. An exemplary phylogenetic tree is shown in Figure 1C, where different subclones gave rise to different LNMs, and several liver metastases with common ancestry were related to the TD. Taken together, TD, LNM, primary tumor or a mix of these were found to be the origin of liver metastases in 23%, 23%, 23% and 30%, respectively (Figure 1D). Several clinicopathological variables were tested for biasing the results, of which only the number of included TDs was significantly different between the liver metastases related to TD and PT (P = 0.03), all other comparisons showed no differences significantly with the number of metastases related to TD (Supplementary Figures S2-S3). Our data show that LNM can form a gateway to liver metastases in 23% of cases, which is in line with an earlier smaller study, where 0-35% of liver metastases were found to be related to LNM [5]. These results are in contrast with the idea that LNM is the main gateway to distant metastases, which is the basis for the current TNM staging system. Importantly, TD were identified as an alternative gateway in 23% of liver metastases, which confirms the prognostic evidence that shows an increased risk of liver metastases in patients with TD [3].

In contrast to liver metastases, peritoneal metastases were most often related to TD with 40% of cases and second most often to the primary tumor with 37%. LNMs or a mix of the different structures formed the origin in 7% and 10% of peritoneal metastases, respectively (Figure 1E). These results provide phylogenetic evidence that supports previous studies showing that the presence of TDs is associated with an increased risk of peritoneal metastases [6].

This study demonstrated a clear difference in the evolution of liver and peritoneal metastases, with a significantly different distribution of origins (P < 0.05, Figure 1D-E) and 40% of peritoneal metastases versus 23% of liver metastases being related to TD. This could be explained by biologically different pathways to metastases. Liver metastases are thought to develop through the invasion-metastasis cascade where tumor cells spread to distant organs via the circulatory system [7]. Both LNMs and TDs formed possible gateways to liver metastases in the phylogenetic analyses and have their own way of accessing the systemic circulation. For LNMs, mouse studies showed that tumor cells could either invade small blood vessels surrounding the lymph node or travel through the lymphatic system and enter the systemic circulation at the thoracic duct [8]. Still, the exact mechanism is being widely debated, and in humans, the mechanism remains unclear. For TDs, it is more widely accepted that they have access to the blood circulation as it is reflected in their histology [4]. In line with literature, our study demonstrated a vascular component in 69% of TD related to liver metastases (Supplementary Figure S4). An alternative to the invasion-metastasis cascade has been proposed for peritoneal metastases involving more direct migration of tumor cells to the peritoneum [7]. We previously showed that the molecular phenotype needed for tumor cells to actively migrate to and invade the peritoneum is overexpressed in TD compared with LNM [9]. Therefore, it is likely that tumor cells with the ability to form TD are also capable of further migration through the serosal surface and invasion of the peritoneum, more so than the tumor cells in LNM.

There are some limitations to this study. Firstly, although all cases complied with the guideline quality of more than 12 sampled lymph nodes per CRC, and TD were scored by two pathologists and an expert researcher, there is a small chance that some TD or LNM were missed during the sampling of resection specimens. Secondly, it would be recommended that all phylogenetic studies be validated using a different method, such as whole genome or exome sequencing, to show whether the results are generalizable and robust [10]. Thirdly, due to time and financial restraints, this study only included the most common metastatic sites in CRC, liver and peritoneum. Including other metastatic sites would provide a more comprehensive overview of the process of metastatic spread in CRC.

In conclusion, with the use of phylogenic analysis, this study shows that both TDs and LNMs can be related to liver or peritoneal metastases in CRC. Moreover, the origin of metastases differs per metastatic site, with liver metastases being equally related to TDs and LNMs and peritoneal metastases being significantly more often related to TDs. Therefore, future research should focus on whether patients with TDs are at increased risk of peritoneal metastases, as this could impact follow-up and treatment decisions. Also, since we showed that a significant number of liver and peritoneal metastases were related to TDs, it should be questioned whether the current method of including TDs as less important than LNMs in the staging for CRC patients is justified. We propose that TDs should merit more attention by including them as equally important to LNMs in the nodal category and continuing to register them for future research.

Conceptualization: Gina Brown, Femke Simmer, Iris Dionne Nagtegaal. Methodology: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Niek Hugen, Femke Simmer, Iris Dionne Nagtegaal. Funding acquisition: Gina Brown, Iris Dionne Nagtegaal. Acquisition and analysis of data: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Shannon van Vliet, Natasja Rutgers. Statistical analysis: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Shannon van Vliet, Natasja Rutgers, Femke Simmer. Material support: Nikki Knijn, Gesina van Lijnschoten, Jessica Juliana Tan, Gina Brown. Writing—original draft: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Niek Hugen, Femke Simmer, Iris Dionne Nagtegaal. Writing—review & editing: Nelleke Pietronella Maria Brouwer, Ayse Selcen Oguz Erdogan, Shannon van Vliet, Natasja Rutgers, Nikki Knijn, Gesina van Lijnschoten, Jessica Juliana Tan, Johannes Hendrik Willem de Wilt, Niek Hugen, Gina Brown, Femke Simmer, Iris Dionne Nagtegaal.

All authors declare no conflicts of interest.

This study was supported by the Dutch Cancer Society (KUN 2019-12640).

The study was performed according to the Dutch “Federa, Human Tissue and Medical Research: Code of Conduct for Responsible Use (2011)” regulations, not requiring patient informed consent. This study was approved by the Ethics Committee (CMO) of the Radboudumc (approval number 2020-7172).

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
揭示结直肠癌远处转移的途径:以肿瘤沉积和淋巴结转移为入口。
在系统发育分析中,LNMs 和 TDs 都是肝转移的可能途径,并且有各自进入体循环的方式。对于淋巴结转移瘤,小鼠研究表明,肿瘤细胞既可以侵入淋巴结周围的小血管,也可以穿过淋巴系统,在胸导管处进入体循环[8]。尽管如此,关于其确切机制仍存在广泛争议,而在人类中,其机制仍不清楚。对于 TDs 而言,更广泛的看法是它们可以进入血液循环,因为这反映在它们的组织学中[4]。与文献一致,我们的研究显示 69% 的 TD 与肝转移有关,其中存在血管成分(补充图 S4)。对于腹膜转移瘤,有人提出了侵袭-转移级联的替代方案,即肿瘤细胞更直接地向腹膜迁移[7]。我们曾发现,与 LNM 相比,TD 中肿瘤细胞主动迁移至腹膜并侵入腹膜所需的分子表型表达过高[9]。因此,有能力形成TD的肿瘤细胞也有能力通过浆膜表面进一步迁移并侵入腹膜,这一点很可能比LNM中的肿瘤细胞更强。首先,虽然所有病例都符合每例 CRC 淋巴结取样超过 12 个的质量标准,而且 TD 由两名病理学家和一名专家研究员进行评分,但在切除标本取样过程中仍有可能漏掉一些 TD 或 LNM。其次,建议所有系统发育研究都使用不同的方法(如全基因组或外显子组测序)进行验证,以显示结果是否具有普遍性和稳健性[10]。第三,由于时间和经费的限制,本研究只包括了 CRC 最常见的转移部位--肝脏和腹膜。总之,通过系统发育分析,本研究表明 TDs 和 LNMs 都与 CRC 的肝脏或腹膜转移有关。此外,每个转移部位的转移来源也不同,肝脏转移与TDs和LNMs的关系相同,而腹膜转移与TDs的关系明显更多。因此,未来的研究应重点关注 TD 患者发生腹膜转移的风险是否会增加,因为这可能会影响随访和治疗决策。此外,由于我们发现大量肝转移灶和腹膜转移灶与 TDs 有关,因此应该质疑目前在对 CRC 患者进行分期时将 TDs 视为不如 LNM 重要的方法是否合理。我们建议,TDs 应得到更多关注,将其作为与 LNMs 同等重要的结节类别,并在未来的研究中继续登记:Gina Brown、Femke Simmer、Iris Dionne Nagtegaal。方法论:Nelleke Pietronella Maria Brouwer、Ayse Selcen Oguz Erdogan、Niek Hugen、Femke Simmer、Iris Dionne Nagtegaal。资金获取:Gina Brown、Iris Dionne Nagtegaal。数据采集与分析Nelleke Pietronella Maria Brouwer、Ayse Selcen Oguz Erdogan、Shannon van Vliet、Natasja Rutgers。统计分析:Nelleke Pietronella Maria Brouwer、Ayse Selcen Oguz Erdogan、Shannon van Vliet、Natasja Rutgers、Femke Simmer。材料支持Nikki Knijn、Gesina van Lijnschoten、Jessica Juliana Tan、Gina Brown。写作-原稿:Nelleke Pietronella Maria Brouwer、Ayse Selcen Oguz Erdogan、Niek Hugen、Femke Simmer、Iris Dionne Nagtegaal。撰稿-审稿-编辑Nelleke Pietronella Maria Brouwer、Ayse Selcen Oguz Erdogan、Shannon van Vliet、Natasja Rutgers、Nikki Knijn、Gesina van Lijnschoten、Jessica Juliana Tan、Johannes Hendrik Willem de Wilt、Niek Hugen、Gina Brown、Femke Simmer、Iris Dionne Nagtegaal。本研究得到了荷兰癌症协会(KUN 2019-12640)的支持。本研究根据荷兰 "人体组织和医学研究联合会"(Federa, Human Tissue and Medical Research:本研究根据荷兰《联邦人类组织和医学研究:负责任使用行为准则(2011)》的规定进行,无需患者知情同意。本研究已获得拉德布鲁德大学伦理委员会(CMO)的批准(批准号2020-7172)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Communications
Cancer Communications Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
25.50
自引率
4.30%
发文量
153
审稿时长
4 weeks
期刊介绍: Cancer Communications is an open access, peer-reviewed online journal that encompasses basic, clinical, and translational cancer research. The journal welcomes submissions concerning clinical trials, epidemiology, molecular and cellular biology, and genetics.
期刊最新文献
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms. Tumor derived cell-free nucleic acid upregulates programmed death-ligand 1 expression in neutrophil via intracellular Toll-like receptor signaling. Wnt/GSK-3β mediates posttranslational modifications of FLYWCH1 to regulate intestinal epithelial function and tumorigenesis in the colon. Engineering heavy chain antibody-drug conjugates against solid tumors for a one-shot kill. Acquired RD3 loss regulates immune surveillance in high-risk and therapy defying progressive neuroblastoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1